Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor Immunity-Reference-Cited by-同舟云学术

Discovery of a Novel Benzodiazepine Series of Cbl-b Inhibitors for the Enhancement of Antitumor Immunity

Published:2023-11-17 Issue:12 Volume:14 Page:1848-1856
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Boerth Jeffrey A.¹^ORCID,Chinn Alex J.¹,Schimpl Marianne²^ORCID,Bommakanti Gayathri³,Chan Christina⁴,Code Erin L.⁵,Giblin Kathryn A.⁶,Gohlke Andrea²,Hansel Catherine S.²,Jin Meizhong¹,Kavanagh Stefan L.⁷,Lamb Michelle L.¹^ORCID,Lane Jordan S.²,Larner Carrie J. B.⁷^ORCID,Mfuh Adelphe M.¹,Moore Rachel K.⁸,Puri Taranee¹,Quinn Taylor R.¹,Ye Minwei³,Robbins Kevin J.¹,Gancedo-Rodrigo Miguel²^ORCID,Tang Haoran²,Walsh Jarrod⁸,Ware Jamie²,Wrigley Gail L.⁶,Reddy Iswarya Karapa³,Zhang Yun¹,Grimster Neil P.¹^ORCID

Affiliation:

1. Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States

2. Discovery Sciences, R&D, The Discovery Centre, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom

3. Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States

4. DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom

5. Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States

6. Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Biomedical Campus, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom

7. Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom

8. High Throughput Screening, Hit Discovery, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.3c00439

Reference36 articles.

1. Mechanisms of tumor escape from the immune system: Adenosine-producing Treg, exosomes and tumor-associated TLRs

2. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

3. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

4. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners